Baidu
map

内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病

2017-12-15 韩国糖尿病协会 Diabetes Metab J. 2017 Dec;41(6):423-429.

胰高血糖素样肽-1受体激动剂2型糖尿病

2017年12月，韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明。在2017年KDA药物治疗糖果尿病的立场声明中，胰高血糖素样肽-1受体激动剂（GLP-1RAs）建议单药应用或者与其他口服降糖药或基础胰岛素联合应用。本文主要针对GLP-1RAs的应用提供建议。

中文标题：

2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病

英文标题：

Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association.

发布机构：

韩国糖尿病协会

发布日期：

2017-12-15

简要介绍：

2017年12月，韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明。在2017年KDA药物治疗糖果尿病的立场声明中，胰高血糖素样肽-1受体激动剂（GLP-1RAs）建议单药应用或者与其他口服降糖药或基础胰岛素联合应用。本文主要针对GLP-1RAs的应用提供建议。

 

拓展指南：与糖尿病相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病)] GetToolGuiderByIdResponse(projectId=1, id=c66081c00153606a, title=2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病, enTitle=Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association., guiderFrom=Diabetes Metab J. 2017 Dec;41(6):423-429., authorId=null, author=, summary=2017年12月，韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明。在2017年KDA药物治疗糖果尿病的立场声明中，胰高血糖素样肽-1受体激动剂（GLP-1RAs）建议单药应用或者与其他口服降糖药或基础胰岛素联合应用。本文主要针对GLP-1RAs的应用提供建议。 , cover=, journalId=null, articlesId=null, associationId=1536, associationName=韩国糖尿病协会, associationIntro=, copyright=0, guiderPublishedTime=Fri Dec 15 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>2017年12月，韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明。在2017年KDA药物治疗糖果尿病的立场声明中，胰高血糖素样肽-1受体激动剂（GLP-1RAs）建议单药应用或者与其他口服降糖药或基础胰岛素联合应用。本文主要针对GLP-1RAs的应用提供建议。 </P> <P> </P>拓展指南：<strong>与<font color=red>糖尿病</font>相关指南：</strong><br><ul><li><a href="//www.sandwebs.com/guideline/show_article.do?id=9bbef1c00153309f" title="2017 SIGN国家临床指南：2型糖尿病患者血糖控制的药物管理（154）" target=_blank>2017 SIGN国家临床指南：2型糖尿病患者血糖控制的药物管理（154）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=8b2a71c00153024c" title="2018 ADA糖尿病诊疗标准" target=_blank>2018 ADA糖尿病诊疗标准</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=b5a591c0015251ed" title="中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）" target=_blank>中国2型糖尿病合并血脂异常防治专家共识（2017年修订版）</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=975a71c001522852" title="关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议" target=_blank>关于2型糖尿病合并慢性肾脏病患者应用胰岛素治疗的专家指导建议</a></li> <li><a href="//www.sandwebs.com/guideline/show_article.do?id=ed10a1c0015200a4" title="2017 TES科学声明：糖尿病性微血管病" target=_blank>2017 TES科学声明：糖尿病性微血管病</a></li> 更多信息请点击：<a href="//www.sandwebs.com/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=31852, tagName=胰高血糖素样肽-1受体激动剂), TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=4, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6927, appHits=218, showAppHits=0, pcHits=4562, showPcHits=2858, likes=202, shares=2, comments=6, approvalStatus=1, publishedTime=Mon Dec 25 22:06:46 CST 2017, publishedTimeString=2017-12-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Dec 25 22:06:46 CST 2017, updatedBy=null, updatedName=null, updatedTime=Wed Jan 03 09:06:34 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病)])
2017 KDA立场声明：胰高血糖素样肽-1受体激动剂治疗2型糖尿病
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=309125, encodeId=77f9309125ab, content=以后英文要好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8822329295, createdName=12268205m49暂无昵称, createdTime=Wed Apr 25 10:17:52 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276185, encodeId=76cd2e6185df, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jan 07 00:27:11 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274499, encodeId=6b9c2e449930, content=客观性.公正性. 讲得很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Jan 01 14:55:14 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273036, encodeId=fb122e3036d2, content=优质资源.共同学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 27 21:45:09 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272519, encodeId=09492e251970, content=2017年12月.韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明.在2017年KDA药物治疗糖果尿病的立场声明中.胰高血糖素样肽-1受体激动剂(GLP-1RAs)建议单药应用或者与其他口服降糖药或基础胰岛素联合应用.本文主要针对GLP-1RAs的应用提供建议., beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Mon Dec 25 23:30:36 CST 2017, time=2017-12-25, status=1, ipAttribution=)]
    2018-04-25 12268205m49暂无昵称

    以后英文要好好学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=309125, encodeId=77f9309125ab, content=以后英文要好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8822329295, createdName=12268205m49暂无昵称, createdTime=Wed Apr 25 10:17:52 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276185, encodeId=76cd2e6185df, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jan 07 00:27:11 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274499, encodeId=6b9c2e449930, content=客观性.公正性. 讲得很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Jan 01 14:55:14 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273036, encodeId=fb122e3036d2, content=优质资源.共同学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 27 21:45:09 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272519, encodeId=09492e251970, content=2017年12月.韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明.在2017年KDA药物治疗糖果尿病的立场声明中.胰高血糖素样肽-1受体激动剂(GLP-1RAs)建议单药应用或者与其他口服降糖药或基础胰岛素联合应用.本文主要针对GLP-1RAs的应用提供建议., beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Mon Dec 25 23:30:36 CST 2017, time=2017-12-25, status=1, ipAttribution=)]
    2018-01-07 虈亣靌

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=309125, encodeId=77f9309125ab, content=以后英文要好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8822329295, createdName=12268205m49暂无昵称, createdTime=Wed Apr 25 10:17:52 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276185, encodeId=76cd2e6185df, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jan 07 00:27:11 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274499, encodeId=6b9c2e449930, content=客观性.公正性. 讲得很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Jan 01 14:55:14 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273036, encodeId=fb122e3036d2, content=优质资源.共同学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 27 21:45:09 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272519, encodeId=09492e251970, content=2017年12月.韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明.在2017年KDA药物治疗糖果尿病的立场声明中.胰高血糖素样肽-1受体激动剂(GLP-1RAs)建议单药应用或者与其他口服降糖药或基础胰岛素联合应用.本文主要针对GLP-1RAs的应用提供建议., beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Mon Dec 25 23:30:36 CST 2017, time=2017-12-25, status=1, ipAttribution=)]
    2018-01-01 虈亣靌

    客观性.公正性. 讲得很不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=309125, encodeId=77f9309125ab, content=以后英文要好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8822329295, createdName=12268205m49暂无昵称, createdTime=Wed Apr 25 10:17:52 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276185, encodeId=76cd2e6185df, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jan 07 00:27:11 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274499, encodeId=6b9c2e449930, content=客观性.公正性. 讲得很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Jan 01 14:55:14 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273036, encodeId=fb122e3036d2, content=优质资源.共同学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 27 21:45:09 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272519, encodeId=09492e251970, content=2017年12月.韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明.在2017年KDA药物治疗糖果尿病的立场声明中.胰高血糖素样肽-1受体激动剂(GLP-1RAs)建议单药应用或者与其他口服降糖药或基础胰岛素联合应用.本文主要针对GLP-1RAs的应用提供建议., beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Mon Dec 25 23:30:36 CST 2017, time=2017-12-25, status=1, ipAttribution=)]
    2017-12-27 虈亣靌

    优质资源.共同学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=309125, encodeId=77f9309125ab, content=以后英文要好好学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8822329295, createdName=12268205m49暂无昵称, createdTime=Wed Apr 25 10:17:52 CST 2018, time=2018-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=276185, encodeId=76cd2e6185df, content=学习了.谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Jan 07 00:27:11 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274499, encodeId=6b9c2e449930, content=客观性.公正性. 讲得很不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Mon Jan 01 14:55:14 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273036, encodeId=fb122e3036d2, content=优质资源.共同学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=144, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 27 21:45:09 CST 2017, time=2017-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=272519, encodeId=09492e251970, content=2017年12月.韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明.在2017年KDA药物治疗糖果尿病的立场声明中.胰高血糖素样肽-1受体激动剂(GLP-1RAs)建议单药应用或者与其他口服降糖药或基础胰岛素联合应用.本文主要针对GLP-1RAs的应用提供建议., beContent=null, objectType=guider, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Mon Dec 25 23:30:36 CST 2017, time=2017-12-25, status=1, ipAttribution=)]
    2017-12-25 有备才能无患

    2017年12月.韩国糖尿病协会(KDA)发布了胰高血糖素样肽-1受体激动剂治疗2型糖尿病的立场声明.在2017年KDA药物治疗糖果尿病的立场声明中.胰高血糖素样肽-1受体激动剂(GLP-1RAs)建议单药应用或者与其他口服降糖药或基础胰岛素联合应用.本文主要针对GLP-1RAs的应用提供建议.

    0

Baidu
map
Baidu
map
Baidu
map